Castle Biosciences revolutionizes dermatologic cancer treatment with DecisionDx®-Melanoma, a test that enhances current staging and predicts prognosis for melanoma patients. By combining traditional staging with genomic insights, DecisionDx®-Melanoma empowers physicians to tailor treatments, improving patient outcomes and quality of life. Castle Biosciences is the future of melanoma management, driving personalized healthcare forward.